With multiple FDA-approved biologics available for patients with psoriatic arthritis, how do we decide which option is best for each patient? Rheumatologist Dr. Joseph Huffstutter details what biologic therapies we have to choose from and the rationale for choosing one over another.
Comparing Biologic Therapies for PsA: Rationales, Benefits, & Risks
You’re listening to Beyond Skin Deep: Impacts of Psoriatic Arthritis on ReachMD, sponsored by Lilly. On this program, we’ll hear from Dr. Joseph Huffstutter, a rheumatologist based in Hixson, Tennessee, who explains the biologic therapies that are available for patients with psoriatic arthritis. Let’s hear from him now.
There are a number of biologics that are FDA-approved to treat psoriatic arthritis. I, as a practicing rheumatologist, am happy to have a number of tools in the toolbox because there’s no medicine that works for every patient. We need to have a variety of tools to help each patient achieve their maximum goal of disease remission. The TNFs were the first agents to be approved for psoriatic arthritis, and they help a wide variety of patients. However, even in the category of TNFs, there are individual variations so that one TNF may work better than another. There are other biologics that have been approved that work by different mechanisms, and I think this is important so that you can individualize therapy for each patient that I see. The toxicities and mechanisms of action differ with each one of these agents so that you may find one agent may be better tolerated than another or one agent may be more efficacious than another.
That was Beyond Skin Deep: Impacts of Psoriatic Arthritis, sponsored by Lilly. To revisit any part of this discussion and to access other episodes in this series, visit ReachMD.com/BeyondSkinDeep, where you can Be Part of the Knowledge. Thanks for listening!
- Guest: J. Eugene Huffstutter, MD
Understanding the needs of a patient with psoriatic arthritis is important when selecting the best treatment option for them.